Medications Development Centers of Excellence (P50)

The summary for the Medications Development Centers of Excellence (P50) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Medications Development Centers of Excellence (P50): -Purpose. This FOA issued by the National Institute on Drug Abuse, National Institutes of Health, solicits Center Grant (P50) applications to provide support for research centers (Medications Development Centers of Excellence) dedicated to clinical research directed towards the identification, evaluation and development of safe and effective medications for treatment of substance related disorders (SRDs), alone or with comorbid conditions. Research may focus on both currently approved and/or novel, investigational medications. -Mechanism of Support. This FOA will utilize the P50 center grant mechanism. -Funds Available and Anticipated Number of Awards. It is anticipated that $7,500,000 in total costs will be awarded to a total of 5-7 applications for this announcement.

Federal Grant Title:	Medications Development Centers of Excellence (P50)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health Education
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-DA-09-002
Type of Funding:	Grant
CFDA Numbers:	93.279
CFDA Descriptions:	Drug Abuse and Addiction Research Programs
Current Application Deadline:	No deadline provided
Original Application Deadline:	Nov 19, 2008
Posted Date:	Aug 27, 2008
Creation Date:	Sep 16, 2008
Archive Date:	Jan 19, 2009
Total Program Funding:	$7,500,000
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: State governments Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Others (see text field entitled "Additional Information on Eligibility" for clarification) Independent school districts Private institutions of higher education For profit organizations other than small businesses Small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Special district governments City or township governments Public and State controlled institutions of higher education Public housing authorities/Indian housing authorities County governments Native American tribal governments (Federally recognized)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: NIH OER Webmaster
[email protected]
[email protected] If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Using Neuromodulation to Characterize the Continuum of Pathophysiology Between Substance U...; • Education Activities for Responsible Analyses of Complex, Large-Scale Data (R25- Clinical ...; • Research on the Neuro-Immune Axis in the context of HIV and Substance Use (R01 Clinical Tr...; • Research on the Neuro-Immune Axis in the Context of HIV and Substance Use (R21 Clinical Tr...; • Developing Digital Therapeutics for Substance Use Disorders (UG3/UH3 Clinical Trial option...; • NIDA Phase II Small Business Innovation Research (SBIR [R44]) Competing Renewal Awards; • Drug Abuse Aspects of Hiv/Aids and Other Infections; • Epidemiology of Drug Abuse
More Grants from the National Institutes of Health: • SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies...; • Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Al...; • Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional); • Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial No...; • Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimenta...